AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01602471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]RDG-K5
Description: Approximately fifteen (15) patients with carotid artery stenosis > 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
Study NCT00957619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxyfilline
Description: The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
Study NCT00957619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
Study NCT00761449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
Study NCT04821388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rontis DCB
Description: The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries
Study NCT03399617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders
Description: Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
Study NCT03399617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient Powders
Description: Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
Study NCT03399617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOON behavioral change strategy
Description: An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
Study NCT03399617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Description: SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
Study NCT01949714 — intervention group
Intervention type: PROCEDURE
Intervention: Removal of adrenal tumor
Study NCT00911755 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal Intubation
Description: This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
Study NCT00911755 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal Intubation
Study NCT01226251 — intervention group
Intervention type: DEVICE
Intervention: In vitro chair side test
Description: Colour evaluation of a strip
Study NCT01872702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: malaria elimination using DP and low-dose primaquine
Description: Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
Study NCT00002829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: Daily
Study NCT00002829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Infused intravenously over 2 hours daily on Day -7 and -6.
Study NCT00002829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered intravenously on Day -8
Study NCT00002829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Beginning 1 hour after initiation of the cyclophosphamide treatment.
Study NCT00002829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplantation
Description: Infusion on Day 0.
Study NCT00002829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Total body irradiation is received on days -4, -3, -2 , and -1.
Study NCT01643226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin solution
Description: 0.12% riboflavin ophthalmic solution
Study NCT01643226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution
Description: 0.0% riboflavin ophthalmic solution
Study NCT01643226 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KXL System
Description: 30 mW/cm2
Study NCT03617978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamics parameters
Description: real-time evaluation of cardiac output parameters using the ICON device
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03007147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV
Study NCT03943459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin 250 mg BID
Study NCT00002833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Cell infusion Day 0.
Study NCT04217889 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Short questionnaire that can be completed during the usual consultation.
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT03635398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sipnose device
Description: SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
Study NCT03635398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAD (Mucosal Atomization Device)
Description: MAD (Mucosal Atomization Device)
Study NCT03635398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: oral administration of midazolam
Study NCT03007147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT02139943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
Study NCT02278289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT02278289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paraffin therapy
Description: Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
Study NCT03447613 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT
Study NCT04751903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral motor stimulation
Description: Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions.It took 15 minutes to apply the OMS by lightly touching their cheeks, lips, gums, and tongue with fingertips for the first 12 minutes, followed by letting the infant suck on a pacifier for the remaining 3 minutes. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants.
Study NCT04096352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Method
Description: Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
Study NCT04096352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Method
Description: Information on voice function and voice hygiene.
Study NCT04096352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indirect Method
Description: Information on voice function and voice hygiene.
Study NCT02139943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
Study NCT02139943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule will be taken orally, before the first meal of the day.
Study NCT01097473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training in outpatient sport groups once weekly with a duration of 60 min each
Study NCT00077376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT04120597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zishen Qingre Lishi Huayu Granules
Description: The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
Study NCT04120597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
Study NCT00077376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT02113072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Description: The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
Study NCT02113072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
Study NCT00077376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02113072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
Study NCT02113072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV
Study NCT00077376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04724382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored healthy eating advice
Description: Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
Study NCT04724382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard healthy eating advice
Description: Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
Study NCT03921255 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Bias Modification
Description: There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO
Study NCT03007147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01643226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KXL System
Description: 30 mW/cm2
Study NCT03033719 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: Open surgery
Study NCT03033719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: Minimally invasive surgery
Study NCT06490575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults
Description: Participants in the intervention group attended four face-to-face workshops (one session per week). Each session took about 30 minutes and consisted of lectures with PowerPoint presentations, discussion, questions and answers, and the distribution of educational pamphlets and booklets.
Study NCT04631887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters in Times of Stress: An Illustrated Guide
Description: The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises.
Study NCT03212794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery coach
Description: The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
Study NCT02032069 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study NCT03440424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: oral tablet
Study NCT03570450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived Stem Cell
Description: 4 doses
Study NCT03799783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: To administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
Study NCT02569866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Capsules containing cephalexin/500mg
Study NCT02569866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing placebo/500mg
Study NCT03921255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Bias Modification
Description: There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
Study NCT01827059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: 125-mg orange-white, round, biconvex, film-coated tablets
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT00866203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDS vs ProMECE/CytaBOM
Study NCT00866203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDS vs ProMECE/CytaBOM
Study NCT01843101 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
Study NCT03007147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01827059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04054349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
Study NCT03282708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh stool collection
Description: One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire
Study NCT03276871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telescopic Dissection
Description: Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
Study NCT02063256 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 7 nuts a day
Description: add 7 nuts a day (whole shelled weight 75 grams) to standard diet
Study NCT00296725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
Study NCT03570450 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01534078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: 2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
Study NCT01534078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin, vinblastine, and dacarbazine
Description: Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
Study NCT03336242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study NCT00742599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-11
Description: 20 ml NPO-11
Study NCT00742599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml NPO-11(Placebo)